Physician profile
Oleg Katcher
NPI 1598701468
$100,489.54
in general payments reported to CMS, 2019-2025
30 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $8,699 · 2021: $18K · 2022: $6,091 · 2023: $16K · 2024: $20K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $6,908 · Consulting Fee: $6,525 · Honoraria: $6,450 · Travel and Lodging: $2,088 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,650.00 |
| Food and Beverage | $6,908.10 |
| Consulting Fee | $6,525.00 |
| Honoraria | $6,450.00 |
| Travel and Lodging | $2,087.78 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,566.04 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $24,229.51 | 2020-2023 | |
| Allergan, INC. | $11,509.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10,490.24 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $9,485.53 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $8,803.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $3,210.62 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,650.59 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $992.14 | 2019-2025 | |
| Ardelyx, INC. | $685.67 | 2022-2025 | Ibsrela |
| Vivus LLC | $314.41 | 2021-2025 | Pancreaze |
| Redhill Biopharma INC. | $283.85 | 2021-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $229.99 | 2020-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $206.48 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $156.00 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $111.92 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $108.86 | 2022-2023 | Dupixent |
| Braintree Laboratories, INC. | $69.53 | 2021-2023 | Sutab, Suflave |
| Astrazeneca Pharmaceuticals Lp | $68.49 | 2025 | Imfinzi |
| Pfizer INC. | $62.04 | 2019-2020 | |
| Janssen Biotech, INC. | $43.45 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $40.82 | 2020 | |
| Daiichi Sankyo INC. | $37.31 | 2020-2021 | |
| Exact Sciences Corporation | $29.09 | 2024 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $21.14 | 2022 | |
| Intra-Sana Laboratories | $19.97 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Shield Therapeutics INC | $17.75 | 2024 | |
| Alfasigma USA, INC. | $17.25 | 2020 | |
| Capsovision, INC. | $14.41 | 2024 | Capsocam Plus |
| Micro-Tech Endoscopy USA, INC. | $13.12 | 2024 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleg Katcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.